Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Inflammatory Breast Carcinoma, Invasive ...
Phase Not Applicable
Enrollment 1200
Locations 10 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This trial studies the biospecimen and medical data collection in creating a research tissue registry in patients with inflammatory or invasive breast cancer. Collecting medical data and storing samples of blood, tissue, and stool from patients with inflammatory breast cancer to study in the laboratory may help doctors find better ways to treat and study inflammatory breast cancer in the future.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Biospecimen Collection — Undergo collection of blood, tissue, and stool
  • Other: Interview — Participate in interview
  • Other: Medical Chart Review — Undergo collection of medical data
  • Other: Questionnaire Administration — Ancillary Studies

Primary Outcomes

  • Data, serum, tissue, peripheral blood mononuclear cells, and plasma sample collection (Up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2007-04-17
Completion: 2030-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI), Texas Appropriation for Rare and Aggressive diseases
Principal Investigators:
  • VIcente Valero, MD (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
Study Contact:
Jie Willey
713-792-3965
jwilley@mdanderson.org
Shakeela Bahadur, MD
480-256-6444
shakeela.bahadur@bannerhealth.com
Banner - MD Anderson Cancer Center
Shakeela Bahadur, MD
Banner - MD Anderson Cancer Center
Interventions
  • Procedure: Biospecimen Collection — Undergo collection of blood, tissue, and stool
  • Other: Interview — Participate in interview
  • Other: Medical Chart Review — Undergo collection of medical data
  • Other: Questionnaire Administration — Ancillary Studies
Study Locations (10 sites)
Banner - MD Anderson Cancer Center, Gilbert, Arizona 85234 United States
Scripps - MD Anderson Cancer Center, La Jolla, California 92037 United States
Banner - MD Anderson Cancer Center - Northern Colorado, Greeley, Colorado 80631 United States
Baptist - MD Anderson Cancer Center, Jacksonville, Florida 32207 United States
Covenant Medical Center, Saginaw, Michigan 48604 United States
M D Anderson Cancer Center, Houston, Texas 77030 United States
MD Anderson in Katy, Houston, Texas 77094 United States
MD Anderson League City, Nassau Bay, Texas 77058 United States
MD Anderson in Sugar Land, Sugar Land, Texas 77478 United States
MD Anderson in The Woodlands, The Woodlands, Texas 77384 United States
Eligibility Criteria
Inclusion Criteria: * Patients with clinical diagnosis of primary inflammatory breast cancer (IBC), second primary IBC, or highly suspicious for IBC (MD Anderson patients only). * Histological diagnosis of invasive breast cancer, or highly suspicious for IBC (MD Anderson patients only) but pending breast cancer diagnosis. * Be either newly diagnosed, or highly suspicious for IBC (MD Anderson patients only) \[Cohort I\] or have paraffin blocks or up to 20 unstained slides of each representative block(s) from the time of initial diagnosis of IBC(i.e. core biopsy and punch biopsy) and/or from mastectomy (Cohort II-MD Anderson patients only) * Age \> 18 years * Able to provide informed consent Exclusion Criteria:
Conditions Breast Cancer
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The primary endpoint of this study is to determine whether cycles of short term FMD exposure to a fasting-mimicking diet is effective in reducing total cholesterol levels.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: FASTING-MIMICKING DIET PROGRAM — Nutritional intervention via fasting-mimicking diet. Patients receiving adjuvant therapy with aromatase inhibitors will be randomized 1:1 into two arms: one intervention, where will receive nutritional counseling and the study diet for 5 days each month for 6 months,and a control one, where they will receive only nutritional counseling.

Primary Outcomes

  • Fasting-mimicking diet (from baseline to the end of treatment at 12 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-01
Completion: 2027-04-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: European Institute of Oncology
Principal Investigators:
  • Giuseppe Curigliano (PRINCIPAL_INVESTIGATOR) - IEO
Contact Information
Study Contact:
Giuseppe Curigliano
+39 02 57489788
giuseppe.curigliano@ieo.it
Ida Minchella
+39 02 94379908
ida.minchella@ieo.it
Interventions
  • Dietary Supplement: FASTING-MIMICKING DIET PROGRAM — Nutritional intervention via fasting-mimicking diet. Patients receiving adjuvant therapy with aromatase inhibitors will be randomized 1:1 into two arms: one intervention, where will receive nutritional counseling and the study diet for 5 days each month for 6 months,and a control one, where they will receive only nutritional counseling.
Study Locations (1 sites)
IEO, Milan, Italy 20141 Italy
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * WHO performance status score 0-2 * Early stage breast cancer, ER positive, receiving an adjuvant endocrine treatment with aromatase inhibitor * Hypercholesterolemic (total cholesterol \>200mg/dL) * Ongoing treatment with aromatase inhibitors (at least six months of drug exposure) * Adequate renal, hepatic, and hematopoietic function * Written and informed consent for biomaterial submission and participation in the clinical trial * Compliance with treatment and follow up protocol * No other investigational agent may be administered concurrently to patients enrolled in this trial * Patients with skeletal pain are eligible if bone scan and/or RX examination fails to disclose metastatic disease * The interval between the onset of systemic adjuvant therapy with AIs and the randomization should be at least 6 months * Patient is accessible geographically for follow-up and must be able to provide dietary data via telephone recalls * Must be medically able to accept either dietary supplementation group prior to randomization. Exclusion Criteria: * Underweight (BMI \< 18.5 kg/m2) * Current or past eating disorders identified with the SCOFF Questionnaire (Useful Eating Disorder screening questions) \[19\] * Malnutrition Universal Screening Tool (MUST). It considers body mass index, weight change and acute disease effect equally and determines a malnutrition risk score. A score ≥1 identify a patient at moderate risk of malnutrition; * Treatment with any investigational or non-registered drug other than the study product(s) within 30 days preceding the first dose of study product, or planned use during the study period * Use of statins or supplements similar to statins (e.g red rice) or other drugs that interfere with lipid absorption (e.g ezetimibe) * Known to have difficult-to-control hypertension, coronary artery disease, arrhythmia requiring treatment, clinically significant valvular disease, cardiomegaly on chest X-ray, ventricular hypertrophy on ECG, previous myocardial infarction, or congestive heart failure Patients with diabetes are not eligible for the study * History of allergic reactions likely to be exacerbated by any component of the investigational product used in the study * Other concurrent, severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk * Previous or concomitant malignancies at other sites, except effectively treated malignancy that is considered by the Investigator to have been cured * Psychiatric or addictive disorders that may compromise the ability to give informed consent or to comply with study procedures.
Conditions Type 2 Diabetes
Phase NA
Enrollment 60
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this trial is to learn if blood flow restriction training with treadmill walking is possible for individuals living with type 2 diabetes. It will also learn about how the blood flow restriction with treadmill walking could improve health. The main questions it aims to answer are: Is 6 weeks of treadmill walking with blood flow restriction reasonable for people with type 2 diabetes to perform? Does treadmill walking with blood flow restriction training help manage type 2 diabetes better than just treadmill walking? Researchers will compare treadmill walking with blood flow restriction to treadmill walking without blood flow restriction to see if blood flow restriction works to manage type 2 diabetes based on fitness and blood sugar levels. Participants will: Perform treadmill walking with or without blood flow restriction for 96 minutes a week for 6 weeks. Visit the lab before and after the exercise for tests and questionnaires.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Aerobic Training with Blood Flow Restriction — Participants will undergo a 6-week aerobic training intervention with blood flow restriction applied to the lower limbs. Blood flow restriction will be applied using a blood pressure cuff set between 60-80% of limb arterial occlusion pressure. Training will consist of treadmill walking at 40-50% of heart rate reserve (HRR) for 32 minutes per session, 3 times per week for a total of 96 minutes per week.
  • Behavioral: Standard Aerobic Training — Participants will follow the same aerobic training protocol as the AT+BFR group but without blood flow restriction. Training will consist of treadmill walking at 40-50% of HRR for 32 minutes per session, 3 times per week for a total of 96 minutes per week.

Primary Outcomes

  • Rate of Recruitment (Every 4 weeks up to 2 years)
  • Rate of Enrollment (Every 4 weeks up to 2 years)
  • Adherence to the Intervention (From enrollment to the end of intervention at week 6)
  • Rate of Retention for Follow-Up Testing (Every 6 weeks up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-01
Completion: 2028-12
Eligibility
Age: 19 Years – 64 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of New Brunswick
Collaborators: Diabetes Canada, University of Guelph, University of British Columbia
Principal Investigators:
  • Martin Senechal, PhD (PRINCIPAL_INVESTIGATOR) - Cardiometabolic Exercise & Lifestyle Laboratory, Fredericton, New Brunswick
Contact Information
Study Contact:
Martin Senechal, PhD
506-451-6889
martin.senechal@unb.ca
Jamie Burr, PhD
519-824-4120
burrj@uoguelph.ca
Jonathan Little, PhD
250-807-9876
jonathan.little@ubc.ca
Exercise Metabolism and Inflammation Laboratory
Interventions
  • Behavioral: Aerobic Training with Blood Flow Restriction — Participants will undergo a 6-week aerobic training intervention with blood flow restriction applied to the lower limbs. Blood flow restriction will be applied using a blood pressure cuff set between 60-80% of limb arterial occlusion pressure. Training will consist of treadmill walking at 40-50% of heart rate reserve (HRR) for 32 minutes per session, 3 times per week for a total of 96 minutes per week.
  • Behavioral: Standard Aerobic Training — Participants will follow the same aerobic training protocol as the AT+BFR group but without blood flow restriction. Training will consist of treadmill walking at 40-50% of HRR for 32 minutes per session, 3 times per week for a total of 96 minutes per week.
Study Locations (3 sites)
Exercise Metabolism and Inflammation Laboratory, Okanagan, British Columbia Canada
Cardiometabolic Exercise & Lifestyle Laboratory, Fredericton, New Brunswick E3B5A3 Canada
Human Performance & Health Research Laboratory, Guelph, Ontario Canada
Eligibility Criteria
Inclusion Criteria: * Diagnosed with type 2 diabetes (5.7% \< HbA1c \< 9.0%) * Not regularly physically active (150 mins moderate-vigorous physical activity per week) Exclusion Criteria: * Musculoskeletal issues preventing exercise training * Unstable medications over the last 3 months * Absolute contraindications to BFR (i.e. peripheral vascular disease) * A self-reported diagnosis of low iron concentrations, anemia, or being treated for these conditions * A diagnosis of any red blood cell-altering condition (i.e., sickle cell anemia, poikilocytosis) * Currently living with any cardiovascular disease, which would impact the ability to participate in exercise safely * Currently prescribed any medication which would impact the ability to use a heart rate monitor to accurately track intensity
Conditions Obesity, Overweight, Type 2 Diabetes Mel...
Phase PHASE3
Enrollment 300
Locations 21 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity, and in participants with T2DM who have obesity or overweight.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Combination Product: Enicepatide — Participants will receive enicepatide via subcutaneous (SC) injection as per the schedule in the protocol.
  • Combination Product: Placebo — Participants will receive matching placebo via SC injection as per the schedule in the protocol.

Primary Outcomes

  • Percent Change From Baseline in Body Weight at Week 52 (Baseline through Week 52)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-07-03
Completion: 2028-03-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hoffmann-La Roche
Principal Investigators:
  • Clinical Trials (STUDY_DIRECTOR) - Hoffmann-La Roche
Contact Information
Study Contact:
Reference Study ID Number: YC46401 https://forpatients.roche.com No attachments to email below.
888-662-6728 (U.S. Only)
global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Interventions
  • Combination Product: Enicepatide — Participants will receive enicepatide via subcutaneous (SC) injection as per the schedule in the protocol.
  • Combination Product: Placebo — Participants will receive matching placebo via SC injection as per the schedule in the protocol.
Study Locations (21 sites)
The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450014 China
Yan'an University Xianyang Hospital, Xianyang, Shaanxi 712000 China
The First Affiliated Hospital of Ningbo University(Ningbo First Hospital), Ningbo, Zhejiang 315010 China
Peking University People's Hospital, Beijing, 100044 China
The Second Hospital of Jilin University, Changchun, 130041 China
The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601 China
The Fourth Affiliated Hospital of Harbin Medical University, Herbin, 150001 China
Huai'an First People's Hospital, Huai'an, China
Huzhou Central Hospital, Huzhou, 313000 China
Jinan Central Hospital, Jinan, 250013 China
Eligibility Criteria
Inclusion Criteria: * Body mass index (BMI) ≥24.0 kilograms per meter squared (kg/m\^2) for participants with type 2 diabetes mellitus (T2DM) * BMI ≥28.0 kg/m\^2 or BMI ≥24.0 and \<28.0 kg/m\^2 and diagnosed with at least one weight-related comorbidity (prediabetes, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea, or weight-related cardiovascular disease) for participants without T2DM * Agreement to adhere to the contraception requirements Exclusion Criteria: * History of Type 1 diabetes mellitus (T1DM) * Obesity induced by other endocrinologic disorders * Any planned major medical procedure or surgery during the study * History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder * Any lifetime history of suicide attempt * History of any hematologic conditions that may interfere with HbA1c measurement * History of acute or chronic pancreatitis or clinically significant gallbladder disease * Treatment with any approved or investigational GLP-1-RA-based therapy within 6 months prior to randomization * Treatment with other investigational therapy within 3 months prior to randomization or less than 5 elimination half-lives prior to randomization, whichever is longer * Known allergy to any component of the study drug formulation or any other condition that is a contraindication to GLP-1 RAs or GLP-1/GIP RAs
Conditions Myocardial Infarction, Diabetes Mellitus...
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

Prospective trials performed on type 2 diabetes patients without established cardiovascular disease has shown that SGLT2 inhibitors reduce cardiovascular risk. No studies have yet examined the occurrence of cardiovascular disease in patients with acute myocardial infarction. The investigators designed the current study to evaluate the most ideal oral hypoglycemic agent in type 2 diabetes patients undergoing percutaneous coronary intervention for acute myocardial infarction. The investigators hypothesize that the use of SGLT-2 inhibitors will reduce cardiovascular events and modify left ventricular remodeling after myocardial infarctions.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: SGLT2 inhibitor — Patients started on SGLT2 inhibitors after PCI for AMI

Primary Outcomes

  • Major adverse cardiac and cerebrovascular events (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-08-01
Completion: 2026-12-31
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kiyuk Chang
Collaborators: Seoul St. Mary's Hospital, Uijeongbu St. Mary Hospital, Incheon St.Mary's Hospital, Daejeon St. Mary's hospital, Bucheon St. Mary's Hospital, St Vincent's Hospital, Yeouido St. Mary's Hospital, Sejong General Hospital, Pusan National University Hospital, Andong Hospital, Chungnam National University Hospital, St. Carollo General Hospital, Pusan National University Yangsan Hospital, Kyungpook National University Hospital, Jeju National University Hospital, Korea University Anam Hospital, Inje University
Principal Investigators:
  • Kiyuk Chang, MD, PhD (PRINCIPAL_INVESTIGATOR) - Seoul St. Mary's Hospital
Contact Information
Study Contact:
Kiyuk Chang, MD, PhD
82-2-2258-1139
kiyuk@catholic.ac.kr
Kiyuk Chang
kiyuk@catholic.ac.kr
Seoul St. Mary's Hospital
Interventions
  • Drug: SGLT2 inhibitor — Patients started on SGLT2 inhibitors after PCI for AMI
Study Locations (1 sites)
Seoul St. Mary's Hospital, Seoul, South Korea
Eligibility Criteria
Inclusion Criteria: * Acute myocardial infarction who were treated with percutaneous coronary intervention * Type 2 diabetes mellitus * Started SGLT2 inhibitors \<1 month before/after PCI Exclusion Criteria: * Type 1 diabetes mellitus * Insulin / GLP-1 analogue users * Previous users of SGLT2 inhibitors * Pregnancy
Conditions Type 2 Diabetes (T2D)
Phase PHASE4
Enrollment 678
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This study is an open-label, 1:1 randomized, active-controlled, 2-arm, 20-week treatment duration, parallel-group, multicenter, phase IV study to evaluate the effect of iGlarLixi versus Gla-100 on glycemic control measured as TIR from CGM device in Chinese insulin naïve patients with T2D inadequately controlled with OADs. At the end of the screening period, eligible participants will be randomized to one of two treatment groups (iGlarLixi or Gla-100 group). The randomization (1:1) will be stratified by values of HbA1c at screening (\<8.0%, ≥8.0%), and background treatment (metformin only, metformin+SGLT-2i). Study details include: * The study duration per participant will be approximately up to 24 weeks. * The treatment duration will be up to 20 weeks. * The number of visits will be 14 visits including 9 times of on-site visits and 5 times of phone call visits in total during screening and treatment periods. On-site every 1 week will be from screening till randomization (Week 0), then on site or phone call visit every 2 weeks till Week 12, then every 3 weeks till Week 18, and the End of Treatment visit will be conducted at Week 20. There will be a safety follow-up by a phone call visit (End of Study) in 3 days (-1/+3 days) after the last dose of the treatment. * Health measurement/Observation: change in TIR as the primary endpoint * Intervention name: iGlarLixi and Gla-100 * Participant gender: male and female * Participant age range: adults at least 18 years of age * Condition/disease: type 2 diabetes * Study hypothesis: compared to Gla-100, iGlarLixi will demonstrate a superiority therapeutic effect on glycemic control assessed by change in TIR measured with CGM from baseline to Week 20 in the study participants.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: iGlarLixi (insulin glargine/lixisenatide) — iGlarLixi will be supplied as a sterile aqueous solution in a pen-injector. There will be 2 pen-injectors with different insulin glargine/lixisenatide fixed ratios which allow insulin glargine titration from 5 U/day to 40 U/day while limiting lixisenatide dose to a maximum of 20 μg/day: \- iGlarLixi must not be mixed with other insulins nor diluted.
  • Drug: Gla-100 (insulin glargine) — Gla-100 will be supplied as a 3 mL sterile aqueous solution for SC injection in a pre-filled disposable Gla-100 SoloStar® pen containing 300 U insulin glargine (100 U/mL). Doses could be set in the range of 5 to 80 U in increments of 1 unit.

Primary Outcomes

  • Superiority of mean change in the percentage of TIR [3.9-10.0 mmol/L (70-180 mg/dL)] (from baseline to Week 20)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-12-10
Completion: 2026-09-18
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 678 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sanofi
Principal Investigators:
  • Clinical Sciences & Operations (STUDY_DIRECTOR) - Sanofi
Contact Information
Study Contact:
Trial Transparency email recommended (Toll free for US & Canada)
800-633-1610
contact-us@sanofi.com
Interventions
  • Drug: iGlarLixi (insulin glargine/lixisenatide) — iGlarLixi will be supplied as a sterile aqueous solution in a pen-injector. There will be 2 pen-injectors with different insulin glargine/lixisenatide fixed ratios which allow insulin glargine titration from 5 U/day to 40 U/day while limiting lixisenatide dose to a maximum of 20 μg/day: \- iGlarLixi must not be mixed with other insulins nor diluted.
  • Drug: Gla-100 (insulin glargine) — Gla-100 will be supplied as a 3 mL sterile aqueous solution for SC injection in a pre-filled disposable Gla-100 SoloStar® pen containing 300 U insulin glargine (100 U/mL). Doses could be set in the range of 5 to 80 U in increments of 1 unit.
Study Locations (1 sites)
Investigational Site Number: 1560001, Beijing, 100730 China
Eligibility Criteria
Inclusion Criteria: * Participants who are diagnosed as T2D of at least 1 year before screening visit * Participants who are treated at least 3 months prior to screening visit with a stable dose of metformin alone or in combination with a second OAD * Inadequate control * Body mass index (BMI) within the range 20-40 kg/m2 (inclusive) * Is willing and able to wear the CGM device continuously * Is willing to discontinue daily (oral) SU, glinide, alpha-GI, and DPP-4i * Not using another CGM device during the study Exclusion Criteria: * Participants with severe renal dysfunction * Participants with short life expectancy * Participants with conditions/concomitant diseases making them non evaluable for the efficacy endpoints * Participants with conditions/concomitant diseases precluding their safe participation in this study * An episode of severe hypoglycemia requiring the assistance of a third party within 3 months before screening visit * History of clinically significant pancreatitis or severe gastrointestinal disorders * Participants who have any history of severe multiple allergies or an allergy resulting in anaphylaxis, or contraindication/hypersensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study * Previous treatment with insulin * Use of any glucose-lowering agents other than metformin alone or in combination with a second OAD (can be a SU, a glinide, an alpha-GI, a DPP-4i, or a SGLT-2i) * Use of systemic glucocorticoids * Use of weight loss drugs * History of discontinuation of a previous treatment with GLP-1 RA for safety/tolerability reasons or lack of efficacy * Laboratory findings at the screening visit * Participants have any current or previous skin conditions * Participants unwilling or unable to do blood glucose monitoring using the Sponsor-provided blood glucometer at home The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Conditions Diabetes Mellitus, Type 2, Insomnia, Sed...
Phase NA
Enrollment 44
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical feasibility trial is to learn whether the investigators can improve sleep and reduce sedentary behaviour in people living with Type 2 diabetes mellitus with sleep problems. The main questions it aims to answer are: • question 1, can objectively measured sleep and sedentary behaviour be improved in the participants and • question 2, what effect will this have on a number of physical and physiological markers. Participants in the intervention group will be asked to keep sleep diaries and attend regular meetings with a qualified coach who will use a specific talking therapy to try to improve sleep and with use behaviour change techniques to help them be less sedentary. Researchers will compare the control group to the intervention group to see if effects differ between groups.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: CBTi — A 12 week intervention using CBTi to improve sleep measured using objective and subjective measures. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.
  • Other: Control - usual care — Participants will be given a leaflet summarising good sleep practice and the advantages of reducing sedentary behaviour. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.
  • Behavioral: Sedentary behaviour reduction — Participants will be encouraged to increase activity and thus reduce sedentary time. Investigators will use behaviour change techniques to aid in this goal. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.

Primary Outcomes

  • Sleep Efficiency (SE) measured using accelerometer data. (Before and after the 12 week intervention/intervention period)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-02
Completion: 2026-07
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 44 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Leicester
Collaborators: University Hospitals, Leicester
Principal Investigators:
  • Melanie Davies, PhD (PRINCIPAL_INVESTIGATOR) - Leicester Diabetes Centre
Contact Information
Study Contact:
Alix HA Covenant, MSc
01162588572
ahac1@leicester.ac.uk
Joe Henson, PhD
1162588572
jjh18@leicester.ac.uk
Alix HA Covenant, MSc
ahac1@leicester.ac.uk
Diabetes Research Centre University Hospitals Leicester
Interventions
  • Behavioral: CBTi — A 12 week intervention using CBTi to improve sleep measured using objective and subjective measures. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.
  • Other: Control - usual care — Participants will be given a leaflet summarising good sleep practice and the advantages of reducing sedentary behaviour. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.
  • Behavioral: Sedentary behaviour reduction — Participants will be encouraged to increase activity and thus reduce sedentary time. Investigators will use behaviour change techniques to aid in this goal. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.
Study Locations (1 sites)
Diabetes Research Centre University Hospitals Leicester, Leicester, Leicestershire LE5 4PW United Kingdom
Eligibility Criteria
Inclusion Criteria: * Diagnosed with Diabetes Mellitus type 2 for longer than 3 months * Participant is willing and able to give informed consent to take part in the study. * Sleep disorder symptom checklist 25 (SDS-CL-25) of ≥5 on insomnia criteria. * Not at high risk of undiagnosed Obstructive Sleep Apnoea (OSA), scoring ≥5 on STOP BANG scale (snoring, tired, observed, pressure, body mass index, age, neck size, gender) diagnosed treated OSA is acceptable. * Glycated haemoglobin (HbA1c) of 10% or less (86 mmol/mol) or less * Male or Females. * ≥ 18 ≤ 75 years of age. * Able to walk without the use of an assistive device or requiring assistance from another person. * Not undertaking more than 75 minutes a week of strenuous exercise or sport. * Not taking opioids * Be treatment stable for at least 3 months * Accelerometer measurement of SE ≤ 85% * An understanding that CBTi may exacerbate sleep deprivation in the short term which may impact on certain aspects of daily life. Exclusion Criteria: * Individuals living with narcolepsy or diagnosed parasomnia * Individuals with type 1 diabetes or gestational diabetes * Recent cardiovascular event (within the last 6 months). * Currently on opioids * Diagnosed with borderline personality disorder, psychosis, adult attention deficit hyperactivity disorder (ADHD) or schizophrenia (self-reported). * Individuals living with epilepsy or seizures. * Shift workers * Female participant planning to become pregnant with the timeframe of the study or is currently pregnant. * Terminal illness.
Conditions Type 2 Diabetes Mellitus (T2DM), MASH - ...
Phase Not Applicable
Enrollment 10000
Locations 22 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This observational study aims to evaluate a new diagnostic tool, the Liver Inflammation Index, in detecting Metabolic Dysfunction-Associated Steatohepatitis (MASH) among adults who have both Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Interventions / Regimen

  • Diagnostic Test: iLivTouch (Vibration-controlled transient elastography) — A non-invasive diagnostic assessment performed using the iLivTouch device. This device simultaneously generates three key metrics: the Liver Inflammation Index (the primary target evaluated for its accuracy in detecting MASH), the Ultrasound Attenuation Parameter (UAP) for hepatic steatosis grading, and the Liver Stiffness Measurement (LSM) for fibrosis staging.

Primary Outcomes

  • To evaluate the overall detection rate of MASH in the Chinese T2DM and MAFLD population. (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-15
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Collaborators: Fudan University, The First Affiliated Hospital of Soochow University, Xuzhou Central Hospital, First Affiliated Hospital of Wenzhou Medical University, The First Affiliated Hospital of Bengbu Medical University, The Second Hospital of Anhui Medical University, The Affiliated Hospital of Qingdao University, Weifang People's Hospital, Panyu Hospital of Traditional Chinese Medicine, Southern Medical University, China, First Affiliated Hospital of Guangxi Medical University, Zunyi Medical College, The First Affiliated Hospital of Air Force Medicial University, Hainan General Hospital, The Third People's Hospital of Yunnan Province, Sir Run Run Shaw Hospital, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Eighth Affiliated Hospital, Sun Yat-sen University, Second Affiliated Hospital of Wannan Medical College, Renmin Hospital of Wuhan University, The First Affiliated Hospital of University of South China
Principal Investigators:
  • Yan Bi, MD,PhD (PRINCIPAL_INVESTIGATOR) - Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
Contact Information
Study Contact:
Yan Bi, MD,PhD
86-25-83-105302
biyan@nju.edu
Jin Li, MD,PhD
86-25-83-105302
jinli807@126.com
Xiaolei Hu
Department of Endocrinology, the First Affiliated Hospital of Bengbu Medical University
Interventions
  • Diagnostic Test: iLivTouch (Vibration-controlled transient elastography) — A non-invasive diagnostic assessment performed using the iLivTouch device. This device simultaneously generates three key metrics: the Liver Inflammation Index (the primary target evaluated for its accuracy in detecting MASH), the Ultrasound Attenuation Parameter (UAP) for hepatic steatosis grading, and the Liver Stiffness Measurement (LSM) for fibrosis staging.
Study Locations (22 sites)
Department of Endocrinology, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004 China
Department of Endocrinology, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601 China
Department of Endocrinology, the Second Affiliated Hospital of Wannan Medical University, Wuhu, Anhui 241000 China
Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510280 China
Department of Obesity and Metabolic Diseases, Panyu Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong 511495 China
Department of Endocrinology, the Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong 518033 China
Department of Endocrinology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021 China
Department of Endocrinology, the Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000 China
Department of Endocrinology, Hainan General Hospital, Haikou, Hainan 570311 China
Department of Endocrinology, the First Affiliated Hospital of Henan University of CM, Zhengzhou, Hennan 450099 China
Eligibility Criteria
Inclusion Criteria: 1. Adults aged ≥18 years, with no restrictions on sex; 2. Patients clinically diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD) according to the Chinese Society of Hepatology guideline Guidelines for the Prevention and Treatment of Metabolic Dysfunction-Associated (Nonalcoholic) Fatty Liver Disease (2024 Edition), and additionally diagnosed with type 2 diabetes mellitus (T2DM) based on the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus (2024 Edition). Exclusion Criteria: 1. Presence of unhealed wounds, scars, or other conditions in the right upper abdominal region that are unsuitable for ultrasonographic examination; 2. Development of other liver diseases during follow-up, including viral hepatitis, drug-induced liver injury, autoimmune liver disease, alcoholic liver disease, or other chronic liver diseases; 3. History of hepatic decompensation; 4. History of hepatectomy or liver transplantation; 5. History of other malignancies; 6. Presence of vascular liver disease, cystic fibrosis-associated liver disease, sarcoidosis, polycystic liver disease, congenital or rare hereditary liver diseases, mechanical cholestasis, secondary sclerosing cholangitis, or heart failure accompanied by hepatic venous congestion; 7. History of transjugular intrahepatic portosystemic shunt (TIPS); 8. Occurrence of acute hepatitis during follow-up (defined as alanine aminotransferase levels \>5 times the upper limit of normal) or acute-on-chronic liver failure (ACLF); 9. Clinical or subclinical hypothyroidism or hyperthyroidism.
Conditions Pre-Gestational Diabetes, Type2diabetes,...
Phase NA
Enrollment 104
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

DIP : To conduct a pragmatic, non-blinded randomized controlled trial (pRCT) of immediate in-patient postpartum OGTT prior to delivery discharge (intervention) versus 4-12 week outpatient postpartum OGTT (current standard care) to improve the frequency of post-partum diabetes screening among individuals with a pregnancy complicated by GDM. Follow up PP CARE: To engage with individuals with a history of GDM through a patient-centered mixed-methods survey and qualitative assessment to evaluate the barriers to and facilitators of Cardiovascular health (CVH) counseling and risk-reduction postpartum at the patient and healthcare system levels inclusive of Social determinants of health (SDOH) and structural factors, as well as patient preferences and perspectives on CVH and wellness interventions

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Immediate inpatient postpartum OGTT — The intervention includes immediate inpatient postpartum 2-hour oral glucose tolerance test (OGTT) prior to delivery discharge
  • Diagnostic Test: Standard of care 4-12 week postpartum OGTT — Standard of care is 4-12 week outpatient postpartum OGTT

Primary Outcomes

  • Rate of postpartum diabetes mellitus screening (From delivery to up to 12 weeks postpartum)
  • Patient reported outcome of postpartum Cardiovascular health (CVH) counseling received within the first 12 months after delivery (Within the first 12 months after delivery)
  • Patient perspectives, preferences and barriers to engagement with respective to postpartum interventions to improve CVH. (Between 12 and 24 months postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-07-24
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 104 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ohio State University
Principal Investigators:
  • Christine Field, MD, MPH (PRINCIPAL_INVESTIGATOR) - Ohio State University
  • Kartik K Venkatesh, MD, PhD (PRINCIPAL_INVESTIGATOR) - Ohio State University
Contact Information
Study Contact:
Kartik Venkatesh, MD, PhD
614-293-2222
kartik.venkatesh@osumc.edu
Kartik Venkatesh, MD, PhD
614-293-2222
Kartik.Venkatesh@osumc.edu
The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine
Interventions
  • Diagnostic Test: Immediate inpatient postpartum OGTT — The intervention includes immediate inpatient postpartum 2-hour oral glucose tolerance test (OGTT) prior to delivery discharge
  • Diagnostic Test: Standard of care 4-12 week postpartum OGTT — Standard of care is 4-12 week outpatient postpartum OGTT
Study Locations (1 sites)
The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine, Columbus, Ohio 43210 United States
Eligibility Criteria
DIP - Inclusion Criteria: * Immediately postpartum individuals during their delivery hospital admission * ≥ 18 years old with the ability to give informed consent. * Diagnosed with GDM during pregnancy by: * Elevated one-hour 50-gram glucose challenge test any time during pregnancy AND provider documentation of gestational diabetes (NOT pregestational diabetes) diagnosis OR * Two elevated values on a 3-hour 100-gram glucose tolerance test any time in pregnancy AND provider documentation of gestational diabetes (NOT pregestational diabetes) diagnosis * English or Spanish speaking * Receiving prenatal and postpartum care at OSU DIP- Exclusion Criteria: * Individuals who cannot tolerate a 2-hour oral glucose tolerance test (OGTT) (i.e. history of gastric bypass) * Not English or Spanish speaking PP CARE Inclusion criteria: Enrolled DIP participants who are English speaking will be eligible for PP CARE follow up if they are between 12 and 24 months postpartum. PP CARE Exclusion criteria: Spanish speaking DIP participants will be excluded because the study team does not include anyone who is Spanish speaking.
Conditions Type 1 Diabetes, Type 2 Diabetes
Phase Not Applicable
Enrollment 900000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

Scarce evidence is available for prognosis in adult-onset type 1 diabetes (T1D). The aim of this study is to investigate the risk of all-cause mortality, cause-specific mortality, and incident CVD in adult-onset T1D, as compared to type 2 diabetes with comparable age at diagnosis and population controls. We will explore potential modifiable factors including lifestyle and clinical characteristics that contribute to T1D prognosis. In addition, we will estimate the life expectancy associated with different age at T1D diagnosis as compared to population controls. This study will be based on people with diabetes recorded in Swedish National Diabetes Registers, with linkages to other nationwide registers to retrieve data on lifestyle factors, biomarkers, treatment and outcome information.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: prognosis of adult-onset t1d — We are comparing mortality and vascular outcomes in adult-onset T1D to T2D and diabetes-free people

Primary Outcomes

  • mortality and vascular outcomes (2001-2022)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-01-01
Completion: 2025-07-01
Eligibility
Age: 18 Years – 110 Years
Sex: ALL
Volunteers: false
Enrollment: 900000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Karolinska Institutet
Principal Investigators:
  • Sofia Carlsson, phd (PRINCIPAL_INVESTIGATOR) - sofia carlsson, senior lecturer, Karolinska Institutet
Contact Information
Study Contact:
Sofia Carlsson, phd
0046 8 524 800 11
sofia.carlsson@ki.se
Yuxia Wei, phd
0046 769266173
yuxia.wei@ki.se
Sofia Carlsson, PhD
+46 8 524 875 00
sofia.carlsson@ki.se
Karolinska institute
Interventions
  • Other: prognosis of adult-onset t1d — We are comparing mortality and vascular outcomes in adult-onset T1D to T2D and diabetes-free people
Study Locations (1 sites)
Karolinska institute, Stockholm, 17177 Sweden
Eligibility Criteria
Inclusion Criteria: * people with adult-onset (≥18 years) T1D diagnosed in 2001-2020 from the National Diabetes Register * all T2D cases diagnosed at age ≥18 years in 2001-2020 recorded in the National Diabetes Register Everyone with T1D was matched by age, sex, and county to 50 population controls from the Total Population Register. Exclusion Criteria: * To avoid diabetes secondary to pancreatic cancer, we excluded people diagnosed with cancer in the digestive system 1 year prior to diabetes diagnosis and with pancreatic cancer as the underlying cause of death.
Conditions Type2diabetes, Obesity
Phase NA
Enrollment 42
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this randomized trial is to determine whether liver fat depletion via a short-term (i.e., two weeks) very-low calorie diet will restore the normal exercise-induced secretion of a signaling protein (fibroblast growth factor 21) from the liver in people living with type 2 diabetes. Participants will have their liver fat, body composition, and various markers of metabolic health assessed and then will be randomized to either the very-low calorie diet intervention or a free-living control group for two weeks. Upon completion of the two-week intervention period, participants will redo all of the pre-intervention assessments. The changes in the assessments from before vs. after the intervention period will be compared between the two intervention groups (i.e., the very-low calorie diet group vs. the free living control group).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Very-low calorie diet — \~800 kcal/day delivered via commercially available diet plan (NUPO).

Primary Outcomes

  • Difference in change in FGF21 incremental area-under-the-curve (4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-01
Completion: 2026-03
Eligibility
Age: 30 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Copenhagen University Hospital, Rigshospitalet
Collaborators: Diabetesforeningen, Canadian Institutes of Health Research (CIHR), Region Hovedstadens Forskningsfond
Principal Investigators:
  • Cody G Durrer, Ph.D. (PRINCIPAL_INVESTIGATOR) - Center for Aktiv Sundhed - Rigshospitalet
Contact Information
Study Contact:
Cody G Durrer, Ph.D.
+4550104538
cody.garett.durrer@regionh.dk
Inge Holm
+4535457621
inge.holm@regionh.dk
Rigshospitalet - CFAS
Cody G Durrer, PhD
Rigshospitalet - CFAS
Interventions
  • Behavioral: Very-low calorie diet — \~800 kcal/day delivered via commercially available diet plan (NUPO).
Study Locations (1 sites)
Rigshospitalet - CFAS, Copenhagen, Capital Region 2100 Denmark
Eligibility Criteria
Inclusion Criteria: * Men and women 30-70 years of age * The target population is persons with type 2 diabetes. I.e., persons are eligible if they are diagnosed with type 2 diabetes either only with metformin for managing glucose or without use of glucose lowering medications. Persons with a HbA1c ≥ 48 mmol/mol with or without the use of glucose lowering medications are also eligible. Any glucose lowering medications other than metformin are disallowed (described under "Exclusion criteria, below) * Diabetes duration \< 7 years * Body Mass Index (BMI) ≥ 30 kg/m2 and ≤ 40 kg/m2 * Accepts medical regulation by the study endocrinologist * Inactivity, defined as \< 1,5 hours of structured physical activity pr. week at moderate intensity and cycling \< 30 minutes/5 km pr. day at moderate intensity (moderate intensity = out of breath but able to speak) Exclusion Criteria: * HbA1c ≥ 75 mmol/mol with no glucose lowering medications * HbA1c ≥ 64 mmol/mol with mono glucose lowering therapy (if compliant with the prescription) * HbA1c ≥ 57 mmol/mol with ≥ dual glucose lowering therapy (if compliant with the prescription) * Diagnosis of Type 1 diabetes, MODY-diabetes, Type 1½ diabetes or LADA-diabetes * eGFR\<60mL/min (assessed via screening blood sample) * Treatment with any glucose-lowering medications other than metformin (e.g., insulin (long and/or short acting), sulphonylurea based drugs, glucagon-like peptide 1 receptor agonists, dipeptidyl peptidase 4 inhibitors, sodium-glucose co-transporter-2 inhibitors, thiazolidinediones, alpha-glucosidase inhibitors) * Presence of metal in the body that would contraindicate an MRI scan * Known or signs of intermediate or severe microvascular complications to diabetes (retino-, neuro- or nephropathy) * Known cancer * Lung disease, other than asthma that can be managed with beta2-agonists and does not exhibit seasonal variation * Known cardiovascular disease * Known hyperthyroid disease * Clinical or biochemical signs of hypothyroid disease * Changes in hypothyroid disease treatment within the last 3 three months prior to enrolment * Known liver disease - defined as ALAT or ASAT elevated three times above upper limit * Known autoimmune disease * Psoriasis disease requiring systemic treatment or cutan elements bigger than a total area of 25 cm2 * Other endocrine disorder causing obesity * Current treatment with anti-obesity medication * Current treatment with anti-inflammatory medication * Weight loss of \> 5kg within the last 6 months * Changes in symptoms or anti-depressive medication three months prior to enrolment * Diagnosis of psychiatric disorder or treatment with anti-psychotic medication * History of suicidal behavior or ideations within the last three months prior enrolment * Previous surgical treatment for obesity (excluding liposuction \> 1 year prior to enrolment) * Pregnant/considering pregnancy, or lactating * Functional impairments that prevent the performance of intensive exercise * Participation in other research intervention studies * Macroalbuminuria at pre-screening (assessed via screening blood sample) * Biochemical sign of other major diseases * Presence of circulating glutamatdecarboxylase anti body (GAD) 65 (assessed via screening blood sample) * Objective findings that contraindicate participation in intensive exercise * Incidental findings that contraindicate participation in the study * Unable to allocate the needed time to fulfill the intervention * Language barrier, mental incapacity, unwillingness, or inability to understand and be able to complete the interventions
Conditions Type 1 Diabetes Mellitus
Phase PHASE2
Enrollment 44
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This study will examine the effects of Tirzepatide (TZP), a glucagon-like peptide 1 (GLP1) - gastric inhibitory peptide (GIP) co-agonist, on metabolism in type 1 diabetes (T1D). Research participants with T1D will undergo measures of insulin sensitivity, and hormone levels post-meal, post-hypoglycemia and during the overnight period. These measures will be performed prior to, and after 6 weeks of treatment with TZP or placebo.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Tirzepatide 2.5mg weekly — Tirzepatide 2.5 mg/0.5 mL solution for injection vial or pre-filled pen. Each vial/ pre-filled pen contains tirzepatide 2.5 mg in 0.5 mL solution (2.5mg in 0.6mL if Kwikpen) Tirzepatide will be administered by drawing up into a syringe, then administering by subcutaneous injection weekly by study nurses.
  • Drug: Placebo injection (normal saline) — Placebo will be given as 0.5mL normal saline (if comparator against vial or pre-filled pen), or 0.6mL (if comparator against Mounjaro Kwikpen), drawn up into a syringe and administered by subcutaneous injection weekly by study nurses.

Primary Outcomes

  • Whole-body insulin sensitivity (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-07-07
Completion: 2027-12-31
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 44 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Victor Chang Cardiac Research Institute
Principal Investigators:
  • Jennifer R Snaith, MD PHD (PRINCIPAL_INVESTIGATOR) - Victor Chang Cardiac Research Institute
  • Jerry R Greenfield, MD PHD (STUDY_DIRECTOR) - Victor Chang Cardiac Research Institute
Contact Information
Study Contact:
Jennifer R Snaith, MD PHD
+61 2 9295 8600
j.snaith@victorchang.edu.au
Jerry R Greenfield, MD PHD
j.greenfield@victorchang.edu.au
Jennifer R Snaith, MD/PhD
61 2 9295 8600
j.snaith@victorchang.edu.au
Victor Chang Cardiac Research Institute
Interventions
  • Drug: Tirzepatide 2.5mg weekly — Tirzepatide 2.5 mg/0.5 mL solution for injection vial or pre-filled pen. Each vial/ pre-filled pen contains tirzepatide 2.5 mg in 0.5 mL solution (2.5mg in 0.6mL if Kwikpen) Tirzepatide will be administered by drawing up into a syringe, then administering by subcutaneous injection weekly by study nurses.
  • Drug: Placebo injection (normal saline) — Placebo will be given as 0.5mL normal saline (if comparator against vial or pre-filled pen), or 0.6mL (if comparator against Mounjaro Kwikpen), drawn up into a syringe and administered by subcutaneous injection weekly by study nurses.
Study Locations (1 sites)
Victor Chang Cardiac Research Institute, Sydney, New South Wales 2010 Australia
Eligibility Criteria
Inclusion Criteria: * age 18-70 years * BMI ≥ 25 kg/m2 * HbA1c ≤ 9.0% * insulin delivery using an automated insulin delivery system * at least 2 years since diagnosis of type 1 diabetes Exclusion Criteria: * TZP or GLP-1 receptor agonist in last 3 months; metformin or sodium glucose co-transporter 2 (SGLT2) inhibitor in the last 6 weeks; systemic steroids, antipsychotics, in the last 6 weeks. * Hypoglycemic unawareness or severe hypoglycemia last 6 months. * History of seizure disorder. * History of weight loss surgery. * eGFR \<60 mL/min/1.73 m2. * Liver disease (known cirrhosis, LFTs \> 3x upper limit of normal). * Active malignancy. * Pregnant, breastfeeding, planning pregnancy within 6 months, or not using adequate contraception. * Coronary event or stroke in last 6 months * Active or untreated proliferative diabetic retinopathy * Hemoglobin level \< 13.5 g/dL in men, \< 12.0 g/dL in women